Human Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor modelSN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions.SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery.Anti-Neoplastic Cytotoxicity of SN-38-Loaded PCL/Gelatin Electrospun Composite Nanofiber Scaffolds against Human Glioblastoma Cells In Vitro.SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells.Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation.OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system.[Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles]Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal FailureLangmuir monolayers and Differential Scanning Calorimetry for the study of the interactions between camptothecin drugs and biomembrane modelsBiotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation
P921
Q28550622-E350648D-A124-4231-B0A9-2241627E9DD9Q35655672-84F3EEED-53C5-4926-97CC-6033B038E435Q35829622-0A8BC11C-1076-4949-A742-DF6FB3EC6FCBQ37071367-8A244D25-4905-4F70-AFAA-04580E1AF9BFQ37671842-4D34BF4E-707C-4845-9914-903853E91353Q38400656-FF22F92C-01D6-484B-A837-6263CB8DE4CBQ38806764-862E339F-AC0D-45E7-B730-17D8BB337F7BQ38809702-62344E7E-B85B-4883-A8A1-849BC03DB7F8Q38824541-FD05D2FD-A6FC-4F65-95D9-CABAB43835F9Q38834678-994A0E91-D597-425E-9955-2900BFCE28F1Q38838759-99316930-7A2B-41A3-A7ED-396D9B55ED5FQ38860619-2F52D42E-21C9-4292-8A40-72E523516DE4Q39114407-28DA6D92-7983-48C5-A4A2-7B13DC3DBF76Q40929836-38C8C164-58AB-4C0E-AADB-0B02A29FF644Q41008169-D88B8C86-3F8C-46A6-8453-0633892741CCQ44913074-B4885A55-545B-4601-B7BC-ED225C6B73CEQ46570170-734E5656-7CB6-475E-89C2-23BAB84902FEQ48680971-0D64337A-1E5A-41EE-89E2-47F01D613216Q85333729-26749018-85BB-4978-BFF2-7FD8C96CFD92Q86067835-46030B00-BC57-44FF-BBA4-1C9D16864C17Q86888092-ACB05891-1355-4C9E-877D-2C194B76DCFFQ87909309-AC9E4E59-7473-40EC-875E-156D7088E771
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
7-ethyl-10-hydroxycamptothecin
@en
SN-38
@fr
SN-38
@it
SN-38
@nl
SN-38
@sh
SN-38
@sr
SN-38
@sr-ec
SN-38
@sr-el
اسان-۳۸
@azb
اسان-۳۸
@fa
type
label
7-ethyl-10-hydroxycamptothecin
@en
SN-38
@fr
SN-38
@it
SN-38
@nl
SN-38
@sh
SN-38
@sr
SN-38
@sr-ec
SN-38
@sr-el
اسان-۳۸
@azb
اسان-۳۸
@fa
altLabel
10-Hydroxy-7-ethylcamptothecin
@en
7-Ethyl-10-hydroxy-20(S)-camptothecin
@en
7-Ethyl-10-hydroxycamptothecin
@en
SN 38 lactone
@en
SN 38
@en
SN38
@it
SN38
@sr
اس ان-38
@fa
اس ان-۳۸
@fa
prefLabel
7-ethyl-10-hydroxycamptothecin
@en
SN-38
@fr
SN-38
@it
SN-38
@nl
SN-38
@sh
SN-38
@sr
SN-38
@sr-ec
SN-38
@sr-el
اسان-۳۸
@azb
اسان-۳۸
@fa
P592
P6366
P661
P662
P665
P683
P1579
P2017
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)[C@@]5(CC)O)O
P2057
HMDB0060510
P2067
392.137222
P231
86639-52-3
P232
P233
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)O)O
P234
1S/C22H20N2O5/c1-3-12-13-7-11( ...... 8H,3-4,9-10H2,1-2H3/t22-/m0/s1
P235
FJHBVJOVLFPMQE-QFIPXVFZSA-N
P2566
100.171.154
P274
C₂₂H₂₀N₂O₅
P3117
DTXSID4040399
P592
P6366
2780508388